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Purpose: MiR-21 and miR-451 are closely associated with tumor initiation, drug resistance,
and recurrence of breast cancer (BC). This study was conducted to evaluate the possible
value of the plasma level of miR-21 and miR-451 as potential biomarkers for the detection of
primary and recurrent BC.
Patients and methods: In this descriptive–analytical study, the plasma level of miR-21
and miR-451 was measured in 23 primary BC patients, 24 recurrent (local/distant metastasis)
BC patients, and 24 aged-match women as healthy controls using quantitative reverse
transcription-polymerase chain reaction (qRT-PCR). Finally, data were analyzed using
SPSS software, and the area under the receiver operating characteristic (ROC) curve of
miRNAs was measured.
Results: The plasma level of miR-21 was signiﬁcantly increased in both groups of primary
(P<0.001) and recurrent (P<0.001) BC patients in comparison with healthy women.
However, the plasma level of miR-451 was not signiﬁcantly changed in primary (P=0.065)
and recurrent (P=0.06) BC patients than healthy controls. The elevation of both miR-21 and
miR-451 plasma level was not signiﬁcantly changed in recurrent patients compared with
non-recurrent (primary) patients (P=0.481, and P=1, respectively). Based on the ROC
analyses, the areas under the curves (AUC) for miR-21 in discriminating primary BC and
recurrent BC patients from healthy controls were 0.828 (95% CI: 0.712 to 0.944) and 0.865
(95% CI: 0.756 to 0.974), respectively.
Conclusion: These data indicating that plasma miR-21 may be useful as a biomarker for the
detection of both primary and recurrent BC. However, plasma miR-451 lacks enough sensi-
tivity in the detection of primary and recurrent BC, and more studies are needed in this area.
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Introduction
Breast cancer (BC) is the most common cancer and the leading cause of cancer
death among females worldwide.1 Most BC-related deaths are because of its
recurrence and distant metastasis, which could be prevented through early diagnosis
of this cancer.2 In some cases, current diagnostic tools lack sufﬁcient speciﬁcity and
sensitivity and are unable to distinguish aggressive from non-aggressive tumors.
For example, mammography, the gold standard diagnostic tool of BC, has a false
positivity of 8-10%, and in young women with dense breast tissue, it does not
exhibit satisfactory sensitivity and speciﬁcity.3,4 Tumor markers such as carcinoem-
bryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) are promising in
BC management, but because of their low sensitivity, they are not useful in early
diagnosis of BC.5–7
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Several studies have shown that microRNAs
(miRNAs), which are ∼22 nucleotides in length, partici-
pated in almost all of the cancers, acting either as tumor
suppressors or oncogenes.8 Circulating miRNAs, includ-
ing serum and plasma miRNAs, not only can be easily
accessed and measured but also can effectively distinguish
cancer patients from healthy individuals.9,10 Among them,
miRNA-21 (miR-21) and miR-451 have drawn more
attention and interest because of their important roles in
the initiation, drug resistance, and development of several
cancers, including BC.11–13 The miR-21 gene is located in
the FRA17B, which is a fragile site that frequently found
to be ampliﬁed in different types of cancers as well as
BC.14 The increasing number of researches indicate that
miR-21 acts as an oncomiR through the repression of
tumor suppressor genes such as Phosphatase and tensin
homolog (PTEN), tropomyosin 1 alpha (TMP1), and
Programmed Cell Death 4 (PDCD4) and incorporates in
drug resistance of tumors.12 The role of miR-21 in tumor-
igenesis after treatment, i.e., recurrence of breast cancer, is
unclear. It is also unclear whether the alteration of its
expression can also be used as a promising plasma biomar-
ker of breast cancer recurrence.
The human miR-451 gene, located at 17q11.2, has been
shown to be widely dysregulated in cancers and plays
roles in tumor initiation and progression.15 In fact, there
are dual reports about miR-451. While some studies have
shown that miR-451 is reduced in cancers and acts as a
tumor suppressor, some suggest an increase in its expres-
sion level in cancer patients than in healthy subjects.16,17
Therefore, more studies are needed to further clarify the
subject. No study has yet been conducted to investigate the
relationship between miR-451 and its potential use as a
plasma biomarker for recurrence of breast cancer.
In this study, we explored the potential value of plasma
miR-21 and miR-451 in discriminating primary and recur-
rent BC patients from healthy controls. Furthermore, we
investigated the differences in plasma level of miR-21 and
miR-451 between the primary and recurrent BC patients,
which have not been identiﬁed to our knowledge.
Materials And Methods
Bioinformatics Study
In addition to the studies and articles, two databases,
dbDEMC 2.0 and miRwayDB, were reviewed for miR-
21 and miR-451.
Study Population
Following written informed consent and questionnaire,
whole blood samples and essential data were collected
from 23 women with primary invasive ductal carcinoma
(IDC) and/or ductal carcinoma in situ (DCIS) BC, and 24
women with local recurrence or distant metastasis of BC
from Parsian Hospital (ShahreKord, Iran) and Seyed Al-
Shohada Hospital (Isfahan, Iran) between 2015 and 2017.
The control group included 24 healthy aged-match women
with no current or previous malignancy, based on the
oncologist conﬁrmation and negative familial history of
BC. Blood samples from primary BC patients, whose
breast tissues showed the tumor for the ﬁrst time and
were in lower stages (I or II), were collected before che-
motherapy. Recurrent BC patients were those with
advanced-stage (IV)/or distant metastatic BC or had
shown the tumor for the second time in their follow-up.
Samples Processing and miRNA
Extraction
Up to 4 mL of whole blood from each participant was
collected in K2EDTA plasma tubes (Sunphoria Co., Ltd
VP3082, Taiwan). Plasma was isolated within 2 h after
blood collection, as follows: EDTA plasma was isolated by
centrifugation (Hettich Mikro 200R, Germany) of whole
blood at 2700 rpm for 7 mins at room temperature. Plasma
supernatant was recovered, divided into aliquots, and
immediately stored at −70°C.
For qRT-PCR analysis, miRNAwas extracted from 250
µL of plasma using miRCURYTM RNA Isolation Kits–
Bioﬂuids (Cat No. 300112, Exiqon, Denmark) according
to the manufacturer’s instructions.
The Efﬁciency Of Primers And
Quantiﬁcation By Real-Time PCR
MicroRNA analysis was performed by SYBR green qRT-
PCR assay. In brief, miRNA was extracted from plasma. A
total of 4.5 µL of isolated total miRNAwas polyadenylated
with the addition of 2 µL poly(A) polymerase buffer, 1 µL
adenosine-triphosphate, and 0.5 µL poly(A) enzyme. Five
microliters of poly(A)-miRNA was reverse transcribed to
cDNAwith the addition of 2 µL 5X ﬁrst strand buffer, 1 µL
deoxynucleoside-5´-triphosphate, 0.5 µL reverse transcrip-
tion enzyme, and 0.5 µL of each cDNA synthesis primers
and was incubated at 44°C for 1 hr. The polyadenylation
and reverse transcription were performed using MiR-Amp
kit (Cat No. 00101005, Parsgenome, Iran).
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The qRT-PCR reaction was performed with the manu-
facturer-provided miRNA-speciﬁc reverse and forward
primers (Cat No. 00101007, Parsgenome, Iran) and
SYBR® Premix Ex Taq™ II (Tli RNase H Plus) (Takara
Bio, Kyoto, Japan) in Rotor-gene 6000® real-time PCR
system (Qiagen, Hilden, Germany). U6 small nuclear
RNA (U6 snRNA) was used as a reference gene. The
total volume of each reaction was 10 µL containing 5 µL
of SYBR Green master mix, 1 µL of cDNA, which was
diluted 15-fold with RNase free water, and 0.4 µL of
miRNA-speciﬁc primers. The process steps were 1 initial
incubation cycle at 95°C for 5 mins, followed by 40
ampliﬁcation cycles of 95°C, 5 s, 63.5°C, 20 s, and 72°
C, 25 s. The run was performed in duplicates for all
samples. To estimate the relative expression level of
miR-21 and miR-451, the difference in the threshold
cycle (Ct) values was assessed between the target and
the endogenous control (U6 snRNA). For more accuracy,
standard curves were generated for each of the miR-21,
miR-451, and U6 snRNA primers using a cDNA serial
dilution of a healthy control sample, which was the same
for all primers.
The efﬁciency of primer from standard curve =
10 (−1/slope) – 1
The fold changes in miR-21 and miR-451 expression
for each primary and recurrent BC samples were calcu-
lated relative to the average expression in normal control
samples. Fold changes were calculated based on the Ct
values using the M. W. Pfafﬂ formula.18
Fold change = (E target gene)
ΔCt target gene/(E reference gene)
ΔCt reference gene
ΔCt target gene = Ct GOI healthy control – Ct GOI patient
sample
ΔCt reference gene = Ct ref healthy control – Ct ref patient
sample
E= efﬁciency of primer
Statistical Analysis
The expression level of miR-451 and miR-21 was com-
pared between the groups using the Kruskal–Wallis test
followed by Dunn test. Receiver operating characteristics
(ROC) curves were established to assess the feasibility of
using plasma levels of miRNAs as diagnostic tools for
differentiating BC patients from controls. All P-values
were 2-tailed and results less than 0.05 were considered
statistically signiﬁcant. All statistical analyses were
performed by SPSS version 18.0 (SPSS Inc., Chicago,
IL, USA). Evaluation of miRNA expression changes was
repeated three times for each sample.
Results
Bioinformatics Results
Regarding the data obtained from the dbDEMC 2.0 data-
base, miR-21 was selected (http://www.picb.ac.cn/
dbDEMC/search.php). Despite numerous articles about
miR-451 on the BC, it has not been included in this
database for this cancer. In the miRwayDB database,
miR-451 only in MCF-7 has been reported (http://www.
mirway.iitkgp.ac.in/search_results). So it looked like that
miR-451 is interesting for our study.
Patient Characteristics
A total of 71 participants including 23 primary BC
patients, 24 local recurrent/or distant metastatic BC
patients, and 24 normal control subjects were recruited.
Details on patient’s specimens, including age, stage, lymph
node metastasis, specimen characteristics (such as hemo-
lysis determined by visual inspection), etc. are summar-
ized in Table 1. There were no signiﬁcant differences in
age between primary BC patients (52.5 ± 10.1 years),
locally recurrent/or metastatic BC patients (49.6 ± 10
years), and controls (45.6 ± 14.3 years) (P = 0.138,
Fisher’s exact test).
The Efﬁciency Of Primers
The linearity of the qRT-PCR between the logarithmic
values of the miRNAs and the Ct values was conﬁrmed
for miR-21, miR-451, and U6 snRNA (R2 = 0.986, R2 =
0.995 and R2 = 0.996, respectively). The efﬁciency of
miR-21, miR-451, and U6 snRNA primers were calculated
as 1.095, 2.02, and 2.06, respectively.
Relative Expression Of Plasma miRNAs
Our data showed that plasma level of miR-21 was signiﬁ-
cantly elevated in both primary BC patients (2.71 folds,
P<0.001) and recurrent BC patients (6.2 folds, P<0.001)
than those in controls. However, the plasma level of miR-
451 was not signiﬁcant between primary and recurrent
patients compared to healthy individuals (P=0.065 and
P=0.06, respectively) (Figure 1). As a side analysis, the
elevated expression levels of both miR-21 and miR-451
were not signiﬁcant between recurrent patients compared
with primary patients (P=0.481 and P=1, respectively).
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Median expression levels of miRNAs in primary BC,
recurrent BC patients, and healthy individuals are pre-
sented in Table 2.
ROC curve analyses revealed that miR-21 was valu-
able in distinguishing both primary BC and recurrent BC
from normal controls with AUCs of 0.828 (95% CI: 0.712
to 0.944) and 0.865 (95% CI: 0.756 to 0.974), respectively
(Figure 2). At the optimal cutoff value of 2.3257 with the
maximal value of sensitivity + speciﬁcity-1 for miR-21 in
discriminating primary BC group from healthy controls,
the sensitivity and speciﬁcity were 60.86% and 95.83%,
respectively. While at the cutoff value of 2.0445 for miR-
21 in discriminating recurrent BC group from healthy
controls, the sensitivity and speciﬁcity were 83.33% and
79.16%, respectively.
Discussion
With respect for searching effective and non-invasive bio-
markers for early BC detection, management, and moni-
toring its relapse during or after the course of treatment to
prolong the survival of BC patients, many studies have
focused on circulating miRNAs.19,20 In the present study,
the levels of two microRNAs (miR-21 and miR-451) were
quantiﬁed in the plasma samples of non-recurrent (pri-
mary) and recurrent BC patients.
Previous researches have shown that blood-based
miRNAs are resistant to RNase degradation, and also
their expression levels are stable and reproducible during
the time and freezing/thaw period.21 Due to easy access
and non-invasiveness of the blood collection process, cir-
culating miRNAs (as plasma miRNAs) have important
roles in the diagnosis and follow-up of cancers.22
Consistent with other studies in gastric cancer,23 lung
cancer,24 colorectal cancer,25 and BC,26 our data also showed
that plasma expression level of miR-21 was signiﬁcantly
higher in both primary and recurrent BC patients than in
healthy subjects. In order to validate the potential role of
plasma miR-21 discriminating primary (early stage) BC
patients and recurrent BC patients from healthy individuals,
more accuracy in predicting recurrent patients (AUC=0.865)
than primary patients (AUC=0.828) was demonstrated. The
increased plasma level of miR-21 in the recurrent group (6.2
times) was higher than the primary group (2.71 times), which
was in line with other reports. Yan et al (2008) showed that
high expression level of miR-21 in BC tissues was signiﬁ-
cantly correlated with advanced clinical stages, poor prog-
nosis, and lymph node metastases of patients.27 Wang et al
(2015) demonstrated that the expression level of miR-21 dis-
tinguishes BC patients from healthy individuals and distant
metastatic BC patients from those with locoregional disease.28
Different mechanisms have been proposed for miR-21
upregulation including gene ampliﬁcation, transcriptional acti-
vation, and post-transcriptional regulation.29 It has been shown
that there are several enhancer sequences upstream of miR-21
Table 1 Clinicopathological Characteristics Of BC Patients
Clinicopathologic
Features
Primary
BC
Recurrent
BC
P-
Value
Grade 0.342
I 8 3
II 4 6
III 4 3
Stage 0.001
I 6 0
II 17 7
III 0 4
IV 0 3
ER 0.621
Positive 5 13
Negative 2 3
PR 1.000
Positive 5 11
Negative 2 5
Her2 0.621
Positive 2 3
Negative 5 13
Node metastasis 0.017
Positive 9 16
Negative 10 8
Histopathology –
ILC 1 2
IDC 14 15
DCIS 7 1
IDC/DCIS 0 2
IDC/ILC 1 1
Site of recurrence –
Breast 0 1
Bone 0 9
Liver 0 5
Lung 0 4
Time of recurrence (month) –
0–12 0 5
12–36 0 4
36–60 0 9
Note: P-values are based on Fisher’s exact test.
Abbreviations: ER, estrogen receptor; PR, progesterone receptor; Her2, human
epidermal growth factor receptor 2; ILC, invasive lobular carcinoma; IDC, invasive
ductal carcinoma; DCIS, ductal carcinoma in situ.
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promoter, which are recognized by different transcriptional
factors such as activation protein 1 (AP-1; composed of Jun
and Fos family), signal transducer and activator of transcrip-
tion 3 (STAT3), serum-response factor (SRF), and nuclear
factor-kappa B (NF-κB). The elevated activity of these factors
through aberrant signaling pathways in cancers could induce
miR-21 upregulation. Moreover, miR-21 regulation could be
affected by post-transcriptional events via the transforming
growth factor β (TGFβ)/bone morphogenetic protein (BMP)
signaling that promotes the maturation of miR-21 by the
DROSHA complex29,30 (Figure 3).
At present, the great immense of miRNAs potentials
has been revealed in the development of novel target-
ing therapies. Chemotherapy, radiotherapy, and
antiendocrine therapy are important components of
therapeutic strategies for cancers. However, the resis-
tance of tumors to these methods is frequently seen in
various cancers which results in cancer recurrence.
Figure 1 Relative expression level of miRNAs in plasma of BC patients and healthy women. The elevation of miR-21 is signiﬁcant in both primary (non-recurrent) and
recurrent patients compared with healthy women. The increased level of miR-451 is not signiﬁcant in patients than in controls. The ratio between the interest miRNAs and
the reference gene was calculated to determine relative expression levels.
Table 2 The Plasma Expression Level Of miR-21 And miR-451
Recurrent BC Primary BC Healthy Individuals
5.6 (2.16–12.47) 2.44 (1.55–4.305) 0.9 (0.672–1.977) miR-21 median (quartiles)
<0.001a <0.001a - P-value
0.481b
2.53 (1.04–6.99) 2.64 (1.15–5.005) 1.32 (0.319–1.887) miR-451 median (quartiles)
0.06a 0.065a - P-value
1b
Notes: P-values are based on Kruskal–Wallis test followed by Dunn test. aBetween BC patients and healthy individuals. bBetween the two BC patient groups.
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Accumulating pieces of evidence have shown that
some miRNAs incorporate in therapy response regula-
tion. MiR-21 is implicated in chemotherapy response
due to the enhancement of resistance of cancer cells to
anti-cancer drugs through the inhibition of PTEN and
PDCD430,31 or by upregulation of multidrug resistance
Figure 2 Validation of miR-21 in BC patients and healthy controls. Graphs of receiver operating characteristics (ROC) curve show the area under the curves (AUCs) of
miR-21 for discriminating the primary BC patients (A) and the recurrent BC patients (B) from the healthy controls. The interval conﬁdence level was 95%.
ERK 1/2
JNKP 38
Fos
family
Jun 
family
STAT3
NF-κB
SRF
TGFβ, BMP 
signaling
Drosha
miR-21
Primary- mir-21
Precursor- mir-21
IL-6
Cytokines; Stress
Growth Factors
Bacterial/Viral infection
UV Irradiation
AP-1
Figure 3 Positive regulation of miR-21 in cancers: Different signaling pathways positively regulate miR-21 expression through the activation of several transcription factors
or by post-transcriptional processing of miR-21.
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type 1 (MDR1), which contribute to the multi-drug
resistance and recurrence of cancers.32 Furthermore, it
also has been demonstrated that miR-21 involves radio-
therapy desensitization.12
Interestingly, some miRNAs play dual roles in different
cancers. They may act as an oncogene or a tumor suppres-
sor. For example, miR-451 plays roles as a tumor suppres-
sor and decreases in tumor tissues compared with normal
adjacent tissues in a variety of cancers.33,34 However,
some studies have indicated that miR-451 may show oppo-
site expression pattern in tumor tissues compared to bio-
ﬂuids such as plasma or serum.35,36 The function of miR-
451 in each cancer depends mainly on the tissue type and
speciﬁc targets.37 For example, one study showed an
increase in the expression of MDR1 in the presence of
miR-451,38 while in another study, MDR1 expression
decreased in the presence of miR-451.39 However, many
studies suggest that miR-451 is a valuable miR in the
initiation, progression, and tumor relapse of some cancers.
In the present study, the elevation of plasma miR-451 in
patient groups versus healthy participants was not signiﬁ-
cant, which is due to the ineffective role of this miR in BC.
However, this ﬁnding may also be due to the small sample
size, different samples, sample collection techniques, and
the normalizing method. Furthermore, miRNAs can be
regulated through different pathways. In our observations,
metastasis to lymph nodes between primary and recurrent
BC is signiﬁcantly different. The results of this difference
had a meaningful relationship within the level expressions
of miR-451 and miR-21.40 The decrease of expression of
miR-451 and increase of miR-21 expression in plasma of
BC patients is related to lymph node metastasis. It is said
that the release of some miRNAs from tumor cells into the
circulation can be selective or circulating miRNAs are
secreted through unknown mechanisms from healthy
tissues.17 But, our laboratory test showed that plasma
miR-451 level was not different in BC, and therefore,
despite the contradictory results regarding this miR in
BC, miR-451 does not seem to serve as a biomarker in
the plasma of BC primary or recurrent patients.
Conclusion
In summary, plasma miR-21 may be a potential biomarker
for the detection of primary BC as well as those patients
who show cancer for the second time in their follow-up
course. On the other hand, miR-451 does not seem to be a
marker for this cancer. Future investigations using larger
sample sizes are needed to evaluate the role of plasma
miR-21 or other plasma miRs associated with primary and
recurrent BC detection. In addition, discriminating differ-
ent groups of patients is needed to develop new prognostic
biomarkers.
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